GILD240830C88000
- 0.01
- 0.000.00%
Gilead Sciences Newsroom
Gilead Sciences: A Balanced Hold Rating Amidst Growth Prospects and Market Challenges
Analysts' Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD) and Premier (PINC)
Wells Fargo Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $78
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $76 to $85
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $76 to $85
Gilead Sciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO) and Gilead Sciences (GILD)
Hold Rating on Gilead Sciences Amid Modest PBC Market Impact
Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (ARQT), Gilead Sciences (GILD) and Cardinal Health (CAH)
Barclays Sticks to Their Hold Rating for Gilead Sciences (GILD)
Gilead Sciences: A Cautious Hold Amidst Mixed Performance and Future Uncertainties
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $72
Deutsche Bank Keeps Their Hold Rating on Gilead Sciences (GILD)
Gilead Sciences (GILD) Gets a Hold From Cantor Fitzgerald
Gilead Sciences: Hold Rating Affirmed Amid Mixed Performance and Cautious Outlook
Gilead Sciences Analyst Ratings
Morgan Stanley Raises Price Target on Gilead Sciences to $79 From $74, Keeps Equalweight Rating
Gilead Sciences Poised for Growth: A Strong Buy Rating With a $93 Price Target
Analysts' Opinions Are Mixed on These Healthcare Stocks: Align Tech (ALGN) and Gilead Sciences (GILD)
Hold Rating on Gilead Sciences Amidst Q2 Revenue Shortfall and Competitive Pressures